Affiliations: The Lautenberg Center for General and Tumor Immunology, IMRIC, The Hebrew University Faculty of Medicine, Jerusalem 91120, Israel
Correspondence:
[*]
Corresponding author: Ofer Mandelboim, The Lautenberg Center for General and Tumor Immunology, IMRIC, The Hebrew University Faculty of Medicine, Jerusalem 91120, Israel. E-mail:oferm@ekmd.huji.ac.il
Abstract: One of the most exciting fields in modern medicine is
immunotherapy, treatment which looks to harness the power of the immune
system to fight disease. A particularly effective strategy uses antibodies
designed to influence the activity levels of the immune system. Here we look
at two receptors - TIGIT and DNAM-1 - which bind the same ligands but have
opposite effects on immune cells, earning them the label `paired receptors'.
Importantly, natural killer cells and cytotoxic T cells express both of
these receptors, and in certain cases their effector functions are dictated
by TIGIT or DNAM-1 signaling. Agonist and antagonist antibodies targeting
either TIGIT or DNAM-1 present many therapeutic options for diseases
spanning from cancer to auto-immunity. In this review we present cases in
which the modulation of these receptors holds potential for the development
of novel therapies.
Keywords: TIGIT, DNAM-1, immunotherapy, cancer, autoimmune disease, NK cells
